Document Type: Editorial

Author

1 Department of Pathology, Imam Hospital, Mazandaran University of Medical Sciences, Sari, Iran

2 Iranian Journal of Pathology Editorial Board

10.30699/ijp.2020.129354.2427

Abstract

Coronaviruses are considered to be one of the most significant human and animal pathogens. In late 2019, a new species of coronavirus was recognized as the cause of some pneumonia cases in Wuhan, China.
The disease spread rapidly and made an epidemic in China and subsequently in almost all countries in the world. In February 2020, the World Health Organization (WHO) named it as COVID-19 standing for Coronavirus 2019 (1).
Due to being a pandemic issue, it is needed to discuss various aspects of this viral disease. Recently, Yan Zhang et al. reported a case of coagulopathy and antiphospholipid antibodies in the patient with severe COVID-19 infection (2). Thus, one of the serious complications of COVID-19 that should be taken into consideration is coagulopathy with possible anti-phospholipid antibodies syndrome in these patients.
In this regard, some studies also claimed that COVID-19 could cause venous and arterial thromboembolism because of excessive inflammation, hypoxia, immobility, and diffuse intravascular coagulation (3). Antiphospholipid syndrome is a systemic autoimmune disease with vascular and hematologic complications as venous and arterial thrombosis or pregnancy morbidity (4).
It is well known that infectious agents are one of the major stimulators of the antiphospholipid antibodies in vivo (5), thus, COVID-19 can be a possible cause of this phenomenon within its infection period and consequently, positive results of  antiphospholipid antibodies detection are not unexpected.

Highlights

Coronaviruses are considered to be one of the most significant human and animal pathogens. In late 2019, a new species of coronavirus was recognized as the cause of some pneumonia cases in Wuhan, China.

Keywords

Main Subjects

  1. Organization WH. Director-General's remarks at the media briefing on 2019-nCoV on 11 Febr uary 2020 -2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).
  2. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. New Engl J Med. 2020 Apr 23;382(17):e38. [DOI:10.1056/NEJMc2007575] [PMID] [PMCID]
  3. Klok F, Kruip M, van der Meer N, Arbous M, Gommers D, Kant K, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. [DOI:10.1016/j.thromres.2020.04.041] [PMID] [PMCID]
  4. Lim W. Antiphospholipid syndrome. Hematol. 2013 Dec 6;2013(1):675-80. [DOI:10.1182/asheducation-2013.1.675] [PMID]
  5. Nasiri N, Golafshan H, Kohan Mozaffari S. New clinical and laboratory finding in anti-phospholipid syndromes. Laboratory & Diagnosis. 2019;11(44):10-8. .
  6. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Apr 29.
  7. Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, MacDonald V, Green L, Sivapalaratnam S, Pasi KJ, MacCallum P. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. New Engl J Med. 2020 May 5. [DOI:10.1056/NEJMc2013656] [PMID] [PMCID]
  8. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18(4):844-7. [DOI:10.1111/jth.14768] [PMID] [PMCID]
  9. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-9. [DOI:10.1111/jth.14817] [PMID]
  10. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020 Apr 9:104362. [DOI:10.1016/j.jcv.2020.104362] [PMID] [PMCID]